Tarek ElBaz, MD. Prof. Internal Medicine Chief, Division of Renal Medicine Al Azhar University President, ESNT

Similar documents
Jo Abraham MD Division of Nephrology University of Utah

Interesting case seminar: Native kidneys Case Report:

Multiple Myeloma Advances for clinical pathologists & histopathologists

Laboratory Examination

Expanding Spectrum of Diseases Associated with Plasma Cell Dyscrasias

Forms Revision: Myeloma Changes

Monoclonal Gammopathies and the Kidney. Tibor Nádasdy, MD The Ohio State University, Columbus, OH

Sheena Surindran Grand Rounds 2/15/11

Lec-14 د.خالد نافع. Medicine. Multiple Myeloma

CASE 3 AN UNUSUAL CASE OF NEPHROTIC SYNDROME

Vasishta Tatapudi, M.D. October 23 rd, 2012.

Plasma cell myeloma (multiple myeloma)

Glomerular pathology in systemic disease

LIGHT CHAIN DISEASE B. DHANALAKSHMI 1 & V. HEMAVATHY 2

Multiple Myeloma 101: Understanding Your Labs

Renal Involvement in Plasma Cell Dyscrasias

FIBRILLARY GLOMERULONEPHRITIS DIAGNOSTIC CRITERIA, PITFALLS, AND DIFFERENTIAL DIAGNOSIS

M-Protien, what to do next? Ismail A Sharif MD, FRCPc Internal Medicine Day 22 nd April 2016

Multiple intra-renal pathological injury patterns in resistant myeloma

Multiple myeloma Biological & Clinical Aspects Isabelle Vande Broek, MD, PhD

Light-Chain Mediated Acute Tubular Interstitial Nephritis. A Poorly Recognized Pattern of Renal Disease in Patients With Plasma Cell Dyscrasia

Dr Ian Roberts Oxford. Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust

Histopathology: Glomerulonephritis and other renal pathology

Renal Transporters- pathophysiology of drug - induced renal disorders. Lisa Harris, Pharmacist, John Hunter Hospital, Newcastle, 2015 November

Quantitative protein estimation of Urine

Instructions for Plasma Cell Disorders (PCD) Post-HCT Data (Form 2116 Revision 3)

Myeloma-induced renal failure: can plasmapheresis help?

CORE CURRICULUM IN NEPHROLOGY Renal Manifestations of Plasma Cell Disorders

Burkitt lymphoma. Sporadic Endemic in Africa associated with EBV Translocations involving MYC gene on chromosome 8

Case Studies: Renal and Urologic Impairments Workshop

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL RESPONSE ASSESSMENT MYELOMA CHAPTER 11C REVISED: SEPTEMBER 2016

Plasma cell dyscrasia with renal impairment including MGRS

Nephroquiz 5: a 51-Year-Old Man With Kidney Failure

Renal Pathology 1: Glomerulus. With many thanks to Elizabeth Angus PhD for EM photographs

5/10/2014. Observation, control of blood pressure. Observation, control of blood pressure and risk factors.

A mathematical model of the effects of multiple myeloma on renal function

Disorders of the kidney. Urine analysis. Nephrotic and nephritic syndrome.

Importancia del laboratorio en el seguimiento clínico de pacientes con mieloma múltiple

Ordering Physician. Collected REVISED REPORT. Performed. IgG IF, Renal MCR. Lambda IF, Renal MCR. C1q IF, Renal. MCR Albumin IF, Renal MCR

Dr Ian Roberts Oxford. Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust

Case Report Nephrotic Syndrome Secondary to Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits of Lambda Light Chain

Understanding the Serum Free Light Chain Assays. Anne L Sherwood, PhD Director of Scientific Affairs The Binding Site, Inc.

RENAL HISTOPATHOLOGY

Pathology of Complement Mediated Renal Disease

Myeloma kidney disease

Michael Joffe ST6 Haematology SpR

Case Report A Case of Proliferative Glomerulonephritis with Monoclonal IgG Deposits That Showed Predominantly Membranous Features

Should we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain

Pathology of the Kidney in Dysproteinemia

The ABCs of Waldenström s Macroglobulinemia (WM)

Quantitative estimation of protein in urine

A Case of IgG2 Heavy Chain Deposition Disease in a Patient with Kappa Positive Plasma Cell Dyscrasia

Major Diagnostic Criteria

Case 3. ACCME/Disclosure. Laboratory results. Clinical history 4/13/2016

Renal Disease in Multiple Myeloma

Management of Multiple Myeloma

Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment

WHO Classification. B-cell chronic lymphocytic leukemia/small T-cell granular lymphocytic leukemia

GENERAL URINE EXAMINATION (URINE ANALYSIS)

Early View Article: Online published version of an accepted article before publication in the final form.

Elevated Serum Creatinine, a simplified approach

Hematology 101. Rachid Baz, M.D. 5/16/2014

Proteinuria. Louisiana State University

Light-chain nephropathy

Amyloidosis. James J. Stark, MD, FACP Medical Director Cancer Program Maryview Medical Center. Professor of Medicine Eastern Virginia Medical

Session Chair: Kenneth C. Anderson, MD Speakers: S. Vincent Rajkumar, MD; Peter Leif Bergsagel, MD; and Donna E. Reece, MD

Szervusz [hi]everybody!

GRAND ROUNDS

Multiple Myeloma: diagnosis and prognostic factors. N Meuleman May 2015

HISTOPATHOLOGY. Shannon Martinson

Stages of Chronic Kidney Disease (CKD)

Osteosclerotic Myeloma (POEMS Syndrome)

Clinical and Pathologic Findings in 52 Consecutively Autopsied Cases With Multiple Myeloma

Freelite SFLC in CKD why use a different reference range? Dr Colin Hutchison Nephrologist Hawke s Bay DHB

EXPERIMENTAL AND THERAPEUTIC MEDICINE 9: , 2015

substance staining with IgG, C3 and IgA (trace) Linear deposition of IgG(+), IgA.M(trace) and C3(+++) at the DEJ

Successful Treatment of Immunoglobulin D Myeloma by Bortezomib and Dexamethasone Therapy

Multiple myeloma evolves from a clinically silent premalignant

RENAL EVENING SPECIALTY CONFERENCE

Hematology Case Conference 8/5/03

Non-protein nitrogenous substances (NPN)

Smoldering Myeloma: Leave them alone!

Haematological Cancer Suspected (Adults & Children)

HIHIM 409 7/26/2009. Kidney and Nephron. Fermamdo Vega, M.D. 1

Surgical Pathology Report

II.Tubulointerstitial diseases

Update on Treatments for Systemic Amyloidosis

BCH 450 Biochemistry of Specialized Tissues

Clinical Significance of ARF. Hospital Acquired Renal Insufficiency. Case - Acute Renal Failure. Hospital Acquired Renal Insufficiency

Glomerular Pathology- 1 Nephrotic Syndrome. Dr. Nisreen Abu Shahin

Case Presentation Turki Al-Hussain, MD

A clinical syndrome, composed mainly of:

HYPERCALCEMIA. Babak Tamizi Far MD. Assistant professor of internal medicine Al-zahra hospital, Isfahan university of medical sciences

The New England Journal of Medicine

MLS Continuing Education Conference November PACE Session # Urinary Casts: The Importance of Laboratory Identification

CASE REPORT Light chain multiple myeloma: an evaluation of its biochemical investigations

Management of Rejection

Pathology of the Hematopoietic System. Case studies

PRINCIPLES OF DIURETIC ACTIONS:

Diuretics (Saluretics)

Transcription:

The Kidney in Multiple Myeloma Tarek ElBaz, MD. Prof. Internal Medicine Chief, Division of Renal Medicine Al Azhar University President, ESNT

Normal Cell Plasma cells produce antibodies that bind to antigens, fighting infection and at times causing disease Plasma cells produce antibodies that bind to antigens, fighting infection and at times causing disease.

Antibodies

Myeloma Cells In multiple myeloma, a malignant transformation occurs producing myeloma cell. These cells produce antibodies in excess.

Multiple Myeloma Definition: Malignant proliferation of plasma cells derived from a single clone MM is a plasma cell dyscrasia that accounts for almost 10% of all hematologic malignancies Etiology: radiation; mutations in oncogenes; familial causes; role of IL 6 Incidence increases with age Males> females ; Blacks > Whites Kyle et al. Cancer 101 : 2667 2674, 2004 Korbet & Shawartz. JASN September 2006 vol.

Clinical Manifestations Bone Pain: 70%, precipitated by movement Pathological fractures Activation of osteoclasts by OAF produced by myeloma cells Susceptibility to infections: Diffuse hypogammaglob. If the M spike is excluded Poor antibody responses, neutrophil dysfunction Pneumococcus, S. aureus: Pneumonia, pyelonephrits Rajkumar. Et al., Mayo Clin Proc 80 : 1371 1382, 2005

Clinical Manifestations Common Bone pain and pathological fractures Anemia and bone marrow failure Infection due to immune-paresis and neutropenia Renal impairment Less common Acute hypercalcemia Symptomatic hyperviscosity Neuropathy Amyloidosis Coagulopathy

Clinical Manifestations Renal failure: 25% Multiple contributory factors Hypercalcemia, hyperuricemia, recurrent infections Tubular damage produced by Light chains type 2 proximal RTA, non selective proteinuria Anemia: 80% Normochromic/normocytic Myelophthisis: inhibition by cytokines produced by plasma cells. Leukopenia/thrombocytopenia only in advanced cases.

Bone Disease 70% cellularity, increased atypical plasma cells comprising 60% of cellularity.

Skull infiltrations

Minimal diagnostic criteria for myeloma >10% Plasma cells in bone marrow or plasmacytoma on biopsy Clinical features of myeloma Plus at least one of: Serum M band (IgG >30 g/l; IgA >20 g/l) Urine M band (Bence Jones proteinuria) Osteolytic lesions on skeletal survey

Epidemiology Serum creatinine > 1.5-2.0 mg/dl The one-year survival is 80% in pts. with Cr < 1.5 compared to 50% in pts. with a Cr > 2.3 Prognosis is especially poor in pts. who require dialysis

Causes of renal failure in MM Cast nephropathy Light chain deposition disease Primary amyloidosis Hypercalcemia Renal tubular dysfunction Volume depletion IV contrast dye, nephrotoxic medications

Start et al., Am J Physiol. 1998;275:F246-F254.

Myeloma Kidney Two main pathogenetic mechanisms: Intracellular cast formation Direct tubular toxicity by light chains Contributing factors to presence of renal failure due to multiple myeloma: High rate of light chain excretion (tumor load) Biochemical characteristics of light chain Concurrent volume depletion

Most common pathological diagnosis on renal biopsy in multiple myeloma Cast Nephropathy Multinucleated giant cells surround the casts Due to light chains binding with Tamm-Horsfall mucoprotein, which is secreted by tubular cells in ascending loop of Henle, forming casts Dehydration worsens cast nephropathy due to decreased flow in tubules, increased concentration of light chains

Cast Nephropathy

Cast Nephropathy

Light Chain Deposition Disease LCDD Most commonly presents with both renal insufficiency and nephrotic syndrome Usually due to kappa (κ) immunoglobulin fragments which deposit in kidneys Circulating light chains are taken up and partially metabolized by macrophages, and then secreted and precipitate, causing tubular injury and thus, proteinuria Korbet and Schwartz. JASN September 2006 vol. 17 no. 9 2533-2545

Uptake of light chains by proximal tubular cells. Renal biopsy specimen from a patient excreting κ light chains. Immunoperoxidase staining showing κ light chains along the brush border and in the cytoplasm of the PTC (brown stain). Batuman et., Am J Physiol. 1998;275:F246-F254.

The tubular basement membranes stained with κ Ig light chain (A) show bright (3+) Monoclonal Ig deposition disease (MIDD) with diffuse and nodular glomerulosclerosis. Courtesy of Jean L. Olson, University of California San Francisco

AL-amyloidosis AL-amyloidosis is found in up to 30% of patients who present with multiple myeloma; conversely, multiple myeloma is present in up to 20% of patients who present with AL-amyloidosis. Proteinuria is the most common renal manifestation at presentation, occurring in up to 80% of patients with the nephrotic syndrome seen in 30 to 50% of these patients. Posi et al. Clin Nephrol 43 : 281 287, 1995

Amyloidosis Usually due to lambda (λ) light chains (AL) Pathogenesis is similar to LCDD, in that light chains are taken up and partially metabolized by macrophages and then secreted then precipitate to form fibrils that are Congo red positive, b-pleated Like LCDD, due to tubular injury and also presents as nephrotic syndrome Kyle. Adv Nephrol Necker Hosp 28 : 383 399, 1998

Renal amyloidosis, ultrastructural appearance. Amyloid deposits are seen as randomly arranged, 10-nM fibrils of indefinite length Glomerulus stained with Congo red

Hypercalcemia Hypercalcemia occurs in multiple myeloma due to bone resorption from lytic lesions Serum calcium > 11.0 mg/dl occurs in 15% of pts with multiple myeloma Hypercalcemia commonly contributes to renal failure by renal vasoconstriction, leading to intratubular calcium deposition

Renal Tubular Dysfunction Acquired Fanconi syndrome On occasion, light chains cause tubular dysfunction without renal insufficiency Most commonly occurs with kappa light chains Light chains are resistant to protease degradation and have tendency to accumulate in tubule epithelial cells and form crystals

Renal Tubular Dysfunction Acquired Fanconi syndrome Renal affection in MM Tubular damage due to light chain toxic effects or indirectly from Two main the release pathogenetic of intracellular lysosomal enzymes mechanisms: Intracellular cast formation This presents as Fanconi syndrome proximal renal tubular Direct acidosis tubular with toxicity wasting by of potassium, phosphate, uric light acid, chains and bicarbonate

Role of IL-6 IL-6 is an important growth factor for plasma cells in multiple myeloma, and may play a role in myeloma kidney IL-6 stimulates acute phase reactants from liver, promoting cast formation and possibly impairing light chain resorption IL-6 also contributes to hypercalcemia by stimulating osteoclasts

Treatment of renal failure in MM Hydration with IV fluids Treatment of hypercalcemia Loop diuretics Caution with bisphosphonates Treatment of myeloma Pulse steroids +/- thalidomide VAD chemotherapy ASCT Possible role for plasmapheresis Dialysis, as necessary

Plasmapheresis in MM Theoretical benefit in removing the toxic circulating light chains to spare renal function Limited data to support efficacy Treatment of choice if hyperviscosity symptoms are present Potential risk for bleeding if Dx is needed due to pheresis-induced removal of coagulation factors

Plasmapheresis in MM

FLCs and cast nephropathy

Plasma exchange is a logical approach, but shows no clinical benefit. A 3.5 L plasma exchange removes 65% of intravascular FLCs but has very little impact on overall FLC levels because they are also present in similar concentrations in the extravascular compartment and tissue edema fluid On the whole, dialyzers are similarly ineffective.

New option for FLC removal Until now, there has been little success in attempts to use blood purification

Perhaps.

Theralite High Cut-off technology It is with a new technology for the efficient and direct removal of FLCs High Cut-off technology is uniquely successful in removing FLCs because its large pores do not restrict removal. Hutchison et al. Clin J Am Soc Nephrol 2009;4:745 754

Prevention of renal failure in MM IVF hydration Discontinuation of nephrotoxic drugs (i.e. NSAIDs, etc.) Chemotherapy/steroids treatment of multiple myeloma to decrease the filtered light chain load